Description | FUNCTION:Playsaroleinautophagy.SUBCELLULARLOCATION:Membrane;multi-passmembraneprotein(Potential).ALTERNATIVEPRODUCTS:3namedisoformsproducedbyalternativesplicing.SIMILARITY:BelongstotheATG9family.INYEAST:FUNCTION:Involvedinautophagyandcytoplasmtovacuoletransport(Cvt)vesicleformation.RecruitesATG23andATG8tothepre-autophagosomalstructure.SUBUNIT:InteractswithATG18,ATG2andATG23.SUBCELLULARLOCATION:Membrane;multi-passmembraneprotein.Preautophagosomalstructure;preautophagosomalstructuremembrane;multi-passmembraneprotein.Note=Pre-autophagosomalandotherperivacuolarpunctatestructures.ThepropertraffickingofATG9betweenthepre-autophagosomalstructureandtheotherpunctatestructuresrequiresATG2,ATG18,ATG23,theATG1-ATG13complexandthephosphatidylinositol3-kinasecomplexI.SIMILARITY:BelongstotheATG9family. |
BatchNo. | Seeproductlabel |
Unitsize | 100µl |
Antigen | Asyntheticpeptide(CWHRRESDESGE)correspondingtotheC-terminalofhumanAPG9A(APG9L1)proteinhasbeenusedastheimmunogen.ThepeptideishomologouswiththecorrespondingsequencederivedfromAPG9A(APG9L1)proteininmouse,rat,S.cerevisiae,Macacamulatta(monkey)andCanisfamiliaris(dog). |
OtherNames | Autophagy-relatedprotein9A;APG9-like1;Autophagy-relatedprotein9;APG9A;ATG9A;APG9L1 |
Accession | ATG9L1_HUMAN ATG9L1_MOUSE ATG9L1_RAT ATG9L1_Saccharomycescerevisiae ATG9L1_Macacamulatta ATG9L1_Canisfamiliaris |
Producedin | Rabbit |
Purity | Wholeserum |
Applications | IHC,immunofluorescence,WB.Adilutionof1:100to1:3000dilutionisrecommendedfortheseapplications.Biosensisrecommendsoptimaldilutions/concentrationsshouldbedeterminedbytheenduser. |
Specificity | IHC,WBandELISAconfirmedthespecificityforATG9A(APG9L1). |
Cross-reactivity | Human,rat.Otherspeciesnotyettested. |
Form | Lyophilised |
Reconstitution | Reconstitutein100µlofsterilewater.Centrifugetoremoveanyinsolublematerial. |
Storage | Afterreconstitutionkeepaliquotsat-20ºCforahigherstABIlity,andat4ºCwithanappropriateantibacterialagent.Glycerol(1:1)maybeaddedforanadditionalstability.Avoidrepetitivefreeze/thawcycles. |
ExpiryDate | Sixmonthsafterpurchase |
SpecificReferences | 1.ParkYEetal(2009)Autophagicdegradationofnuclearcomponentsinmammaliancells.Autophagy.2009Aug;5(6):795-804. |
References | 1.OtaT,eal.Nat.Genet.36:40-45(2004). 2.DelaveauT.T.D,etal.Yeast12:1587-1592(1996). 3.JacqC,etal.Nature387:75-78(1997). 4.TsukadaM.,OhsumiY.FEBSLett.333:169-174(1993). 5.HardingT.M,etal.J.CellBiol.131:591-602(1995). 6.HardingT.M,etal.J.Biol.Chem.271:17621-17624(1996). 7.LangT,etal.J.Bacteriol.182:2125-2133(2000). 8.NodaT,etal.J.CellBiol.148:465-480(2000). 9.KimH,etal.Proc.Natl.Acad.Sci.U.S.A.103:11142-11147(2006). 10.TuckerK.A,etal.J.Biol.Chem.278:48445-48452(2003). |
Biosensis专注于神经科学领域的抗体和试剂的开发,特别是神经营养因子和神经营养因子受体。 近30年来,Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子,我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症(AD)、帕金森氏症(PD)和肌萎缩侧索硬化(ALS)疾病,以及自噬和代谢应激障碍,包括肥胖、代谢综合征的研究、神经免疫学和炎症。